Date: July 8, 2022  Administrative Circular: 2022:28

ATTN: Medical Health Officers and Branch Offices
     Public Health Nursing Administrators and Assistant Administrators
     Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
    Part 4 – Biological Products

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine Eligibility

- Eligibility for a second booster has been expanded to those 18 years of age and older.
- Footnote E has been added to indicate that a second booster dose is recommended for
  residents of LTC, alternate level of care clients awaiting placement in LTC, individuals 70
  years of age and older, and Indigenous persons 55 years of age and older. All others 18
  years of age and older may receive a second booster dose now should they wish to,
  however it is preferable to delay their second booster dose until the fall.
- Appendix C has been removed.

Please remove page numbers: 1-3 dated June 24, 2022
Please add new page numbers: 1-3 dated July 8, 2022

All of the COVID-19 product pages below have been updated to indicate that a second
booster dose is recommended for residents of LTC, alternate level of care clients awaiting
placement in LTC, individuals 70 years of age and older, and Indigenous persons 55 years
of age and older. All others 18 years of age and older may receive a second booster dose
now should they wish to, however it is preferable to delay their second booster dose until the
fall.

COVID-19 Vaccine COMIRNATY® (Pfizer-BioNTech) (Adult/Adolescent)

Please remove page numbers: 1-6 dated May 13, 2022
Please add new page numbers: 1-6 dated July 8, 2022
COVID-19 Vaccine SPIKEVAX™ (Moderna)

Please remove page numbers: 1-5 dated May 13, 2022
Please add new page numbers: 1-5 dated July 8, 2022

COVID-19 Vaccine VAXZEVRIA™/COVISHIELD (AstraZeneca/Verity Pharmaceuticals)

Please remove page numbers: 1-4 dated May 13, 2022
Please add new page numbers: 1-4 dated July 8, 2022

COVID-19 Vaccine (Ad26.COV2.S [recombinant]) (Janssen Inc.)

Please remove page numbers: 1-4 dated June 10, 2022
Please add new page numbers: 1-4 dated July 8, 2022

COVID-19 Vaccine NUVAXOVID™ (Novavax)

Please remove page numbers: 1-3 dated May 13, 2022
Please add new page numbers: 1-3 dated July 8, 2022

Monkeypox Vaccine

Smallpox and Monkeypox Vaccine (Live attenuated, non-replicating): IMVAMUNE®

ADMINISTRATION: Content under Storage and Handling has been updated to include the time required to thaw a vial at room temperature.

Please remove page numbers: 1-3 dated June 30, 2022
Please add new page numbers: 1-3 dated July 8, 2022

Monkeypox Vaccine Client Information Sheet

Minor content revisions have been made to the client information sheet.

Please remove page numbers: 1-2 dated June 30, 2022
Please add new page numbers: 1-2 dated July 8, 2022
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:
Provincial Health Officer
Dr. Bonnie Henry

Dr. Reka Gustafson
Vice President, Public Health & Wellness, PHSA & Deputy Provincial Health Officer

Deputy Provincial Health Officer
Dr. Martin Lavoie

BC Ministry of Health, Population & Public Health Division:
Brian Sagar
Senior Director Communicable Disease, Population and Public Health Division

Bernard Achampong
Executive Director, Public Health, Planning and Prevention, Population and Public Health Division